Table 2.
Shared clonotypes among patients with anti-NMDAR encephalitis.
| Patient ID | Heavy chain | Light chain | |||||||
|---|---|---|---|---|---|---|---|---|---|
| IGHV | IGHD | IGHJ | CDR3 AA | CDR3 _SHM | IGLV | IGLJ | CDR3 AA | CDR3_SHM | |
| PA21 PA22 PA23 PA25 PA29 |
1-18*04 | 1-26*01, 2-2*03, 2-8*01 |
3*02 | ARVGSKYGFETFDI | 0 | 1-44*01 | 3*02 | AAWDDSLNGPV | 0 |
| PA21 PA22 PA23 |
1-18*04 | 1-26*01, 2-2*03, 2-8*01 |
3*02 | ARVGSKYGFETFDI | 0 | 1-40*01, 1-40*02 |
3*02 | QSYDRSLSGYWV | 1 |
| PA8 PA22 PA30 |
1-18*04 | 1-26*01, 2-2*03, 2-8*01 |
3*02 | ARVGSKYGFETFDI | 0 | 1-44*01 | 2*01, 3*01 |
AAWDDSLTGVV | 2 |
| PA11 PA31 |
4-39*01 | 6-6*01 | 4*02 | ARRSSGVRIAARRPFDC | 0 | 2-11*01 | 3*02 | SSYVRAWV | 1 |
CDR3 AA, CDR3 amino acids; SHM, Somatic hypermutation.